Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-15
2008-01-15
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S317000, C514S338000, C514S339000, C544S405000, C544S406000, C544S325000, C544S326000, C546S277400
Reexamination Certificate
active
07319100
ABSTRACT:
Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II):Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.
REFERENCES:
patent: 4296114 (1981-10-01), Appleton et al.
patent: 5223505 (1993-06-01), Hargreaves et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5395817 (1995-03-01), Pallos et al.
patent: 6245769 (2001-06-01), Arvanitis
patent: 4029648 (1992-03-01), None
patent: 94/13676 (1994-06-01), None
patent: 95/10506 (1995-04-01), None
patent: 97/35539 (1997-10-01), None
patent: 97/35846 (1997-10-01), None
patent: 97/44308 (1997-11-01), None
patent: 97/44326 (1997-11-01), None
patent: 98/03510 (1998-01-01), None
patent: 98/11075 (1998-03-01), None
patent: 99/01439 (1999-01-01), None
patent: 99/01454 (1999-01-01), None
patent: 99/11643 (1999-03-01), None
patent: 99/51608 (1999-10-01), None
patent: 00/01675 (2000-01-01), None
patent: 00/11003 (2000-03-01), None
Mitchell, Neurosci. Biobehav. Rev. 22(5); 635-651, 1998.
Kehne, J. H., CNS Neurol Disord Drug Targets, 693): 163-182, 2007.
Arato, M. et al.,Biol. Psychiatry, 1989, 25, 355.
Banki, C.M. et al.,Am. J. Psychiatry, 1987, 144, 873.
Battaglia, G. et al.,Synapse, 1987, 1, 572.
Berridge, C.W. et al.,Horm. Behav., 1987, 21, 393.
Berridge, C.W. et al.,Regul. Peptides, 1986, 16, 83.
Blalock, J.E.,Physiological Reviews, 1989, 69, 1.
Brain Research Reviews, 1990, 15, 71.
Britton, D.R. et al.,Life Sci., 1982, 31, 363.
Britton, K.T. et al.,Psychopharmacology, 1985, 86, 170.
Britton, K.T. et al.,Psychopharmacology, 1988, 94, 306.
Chrousos, G.P.,Int. J. Obesity, 2000, 24(Supp 2), S50-S55.
DeSouza, E.B. et al.,J. Neurosci., 1985, 5, 3189.
DeSouza, E.B.,Hosp. Practice, 1988, 23, 59.
France, R.D. et al.,Biol. Psychiatry, 1988, 28, 86.
Gilligan, P.J. et al.,J. Med. Chem., 2000, 431641-1660.
Gold, P.W. et al.,Am. J. Psychiatry, 1984, 141, 619.
Gold, P.W. et al.,New Eng. J. Med., 1986, 314, 1129.
Green et al.,Protecting Groups in Organic Synthesis, 1991, Wiley, NY.
Grigoriadis et al.,Neuropsychopharmacology, 1989, 2, 53.
Hawley's Condensed Chemical Dictionary, 1997, 13(sup.), J. Wiley & Sons, NY.
Heck, R.F. et al.,Acc. Chem. Res., 1979, 12, 146.
Hirota, K. et al.,J. Org. Chem., 1992, 57, 5268.
Holsboer, F. et al.,Psychoneuroendocrinology, 1984, 9, 147.
Koob, G.F. et al., “Corticotropln-Releasing Factor: Basic and Clinical Studies of a Neuropeptide,” 1990, 221.
Koob, G.F.,Ann. N.Y. Acad. Sci., 2000, 909, 170-185.
Koob, G.F.,Persp. Behav. Med., 1985, 2, 39.
Larock, R.C. et al.,Tetrahedron Let., 1987, 44, 5291.
Maillot, C. et al.,Gastroenterology, 2000, 119, 1569-1579.
March, J.,Advanced Organic Chemistry, 1992, Wiley, NY.
Mastorakos, G. et al.,Ann. N.Y. Acad. Sci., 2000, 900, 95-106.
McCarthy, J.R. et al.,Curr. Pharm. Res., 1999, 5, 289-315.
Morley, J.E.,Life Sci., 1987, 41, 527.
Munson, J. et al.,Anal. Biochem., 1980, 107, 220.
Nemeroff, C.B. et al.,Arch. Gen. Psychiatry, 1988, 45, 577.
Nemeroff, C.B. et al.,Science, 1984, 226, 1342.
Newport, D.J. et al.,Curr. Opin. Neurobiology, 2000, 10, 211-218.
Ojea, V. et al.,Tetrahedron, 1998, 54(5/6), 927-934.
Owens, M.J. et al.,Expert Opin. Invest. Drugs, 1999, 8, 1849-1858.
PCT International Search Report dated Sep. 19, 2002, (PCT/US02/15493).
Ratovelomanana, V. et al.,Tet. Letters, 1984, 52, 6001.
Remington's Pharmaceutical Sciences, 1985, 17(sup)ed., Mack Pub. Co, Easton, PA, 1418.
Rivier, J. et al.,Proc. Nat. Acad. Sci.(USA), 1983, 80, 4851.
Sapolsky, R.M.,Arch. Gen. Psychiatry, 1989, 46, 1047.
Swerdlow, N.R.,Psychopharmacology, 1986, 88, 147.
Tamura, Y. et al.,Chem. Pharm. Bull, 1984, 32, 1995.
Tamura, Y. et al.,Synthesis, 1981, 534.
Vale, W. et al.,Rec. Prog. Horm. Res., 1983, 39, 245.
Vale, W. et al.,Science, 1981, 213, 1394.
Vekemans, J. et al.,J. Heterocyclic Chem., 1982, 20, 919.
Webster, E. et al.,Ann. N.Y. Acad. Sci., 1998, 840, 21-32.
Arvanitis Argyrios G.
Gilligan Paul J.
Hartz Richard A.
Balasubramanian Venkataraman
Bristol-Myers Squibb Pharma Company
Makujina Shah R.
Woodcock & Washburn LLP
LandOfFree
Substituted pyrazinones, pyridines and pyrimidines as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazinones, pyridines and pyrimidines as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazinones, pyridines and pyrimidines as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2753501